login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
NEUMORA THERAPEUTICS INC (NMRA) Stock News
USA
-
Nasdaq
- NASDAQ:NMRA -
US6409791000
-
Common Stock
2.275
USD
+0 (+0.22%)
Last: 12/4/2025, 8:00:02 PM
2.2901
USD
+0.02 (+0.66%)
After Hours:
12/4/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
NMRA Latest News, Press Relases and Analysis
All
Press Releases
a month ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
a month ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
a month ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics to Participate in Upcoming Conferences in November
a month ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics to Participate in Upcoming Conferences in November
4 months ago - By: Benzinga
- Mentions:
OEC
VTLE
DIN
INSE
...
Earnings Scheduled For August 6, 2025
a month ago - By: Benzinga
- Mentions:
DYN
PRE
GNTA
RNA
...
12 Health Care Stocks Moving In Monday's Pre-Market Session
a month ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
a month ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
a month ago - By: Stocktwits
- Mentions:
VHT
SCHA
Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies
a month ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
a month ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
2 months ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics to Host Virtual R&D Day on October 27
2 months ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics to Host Virtual R&D Day on October 27
3 months ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics to Participate in Upcoming Conferences in September
3 months ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics to Participate in Upcoming Conferences in September
4 months ago - By: The Motley Fool
Neumora (NMRA) Q2 Loss Improves 10%
4 months ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
4 months ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
4 months ago - By: Yahoo Finance
Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating
5 months ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
5 months ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
5 months ago - By: Yahoo Finance
Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating
5 months ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
5 months ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
7 months ago - By: Kuehn Law, PLLC
Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm
7 months ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
7 months ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
7 months ago - By: Neumora Therapeutics, Inc.
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
Please enable JavaScript to continue using this application.